Keyword: Turing Pharmaceuticals
The year 2016 was a year of both stability and uncertainty in healthcare finance. FierceHealthFinance looks back at the most significant events of 2016 and what's ahead in 2017.
Pfizer considers Medicaid pricing to be the equivalent of trade secrets.
Martin Shkreli, who became infamous after jacking up the price of a generic AIDs drug and boasting about it online, was arrested on securities fraud charges in December. Court documents allege that Shkreli ran Turing essentially like a Ponzi scheme: after losing considerable amounts of money for investors, he would lie about the losses and pull funds from his other companies to pay the debts.
ARIAD Pharmaceuticals' decision to raise the price of its leukemia drug to nearly $200,000 a year has drawn the attention of some of the most prominent members of Congress.
Hospitals are bearing a large burden for skyrocketing drug costs, healthcare execs said at a recent press conference.
Presidential candidates Hillary Clinton and Donald Trump both have proposals that would likely curb the pricing practices of the pharmaceutical sector.
Hospitals say Valeant Pharmaceuticals has yet to provide promised discounts for its two heart drugs.
Myan's decision to introduce a cheaper version of its EpiPen product raises questions about the moral responsibility of drug companies and their pricing practices.